Publikationen in Zusammenarbeit mit Forschern von Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (25)

2024

  1. Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human

    Vascular Pharmacology, Vol. 155

2023

  1. Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model (Frontiers in Pharmacology, (2023), 14, (1021535), 10.3389/fphar.2023.1021535)

    Frontiers in Pharmacology

  2. Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

    Frontiers in Pharmacology, Vol. 14

  3. Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities

    PLoS pathogens, Vol. 19, Núm. 1, pp. e1011063

  4. The novel KV7 channel activator URO-K10 exerts enhanced pulmonary vascular effects independent of the KCNE4 regulatory subunit

    Biomedicine and Pharmacotherapy, Vol. 164

2021

  1. Oxygen-sensitivity and pulmonary selectivity of vasodilators as potential drugs for pulmonary hypertension

    Antioxidants, Vol. 10, Núm. 2, pp. 1-14

  2. Restoration of vitamin d levels improves endothelial function and increases task-like k+ currents in pulmonary arterial hypertension associated with vitamin d deficiency

    Biomolecules, Vol. 11, Núm. 6

2020

  1. Uncovered Contribution of Kv7 Channels to Pulmonary Vascular Tone in Pulmonary Arterial Hypertension

    Hypertension, Vol. 76, Núm. 4, pp. 1134-1146

  2. Vitamin D deficiency downregulates TASK-1 channels and induces pulmonary vascular dysfunction

    American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 319, Núm. 4, pp. L627-L640

2019

  1. Activation of Kv7 channels as a novel mechanism for NO/cGMP-induced pulmonary vasodilation

    British Journal of Pharmacology, Vol. 176, Núm. 13, pp. 2131-2145

  2. Elevated pulmonary arterial pressure in Zucker diabetic fatty rats

    PLoS ONE, Vol. 14, Núm. 1

  3. Th2 CD4+ T Cells Are Necessary and Sufficient for Schistosoma-Pulmonary Hypertension

    Journal of the American Heart Association, Vol. 8, Núm. 15, pp. e013111

  4. miR-1 induces endothelial dysfunction in rat pulmonary arteries

    Journal of Physiology and Biochemistry, Vol. 75, Núm. 4, pp. 519-529

  5. miR-1 is increased in pulmonary hypertension and downregulates Kv1.5 channels in rat pulmonary arteries

    Journal of Physiology, Vol. 597, Núm. 4, pp. 1185-1197

2018

  1. HIV transgene expression impairs K+ channel function in the pulmonary vasculature

    American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 315, Núm. 5, pp. L711-L723

  2. Pulmonary Arterial Hypertension Affects the Rat Gut Microbiome

    Scientific Reports, Vol. 8, Núm. 1

  3. Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/ perfusion matching

    PLoS ONE, Vol. 13, Núm. 1

2017

  1. Role of acid sphingomyelinase and IL-6 as mediators of endotoxin-induced pulmonary vascular dysfunction

    Thorax, Vol. 72, Núm. 5, pp. 460-471

2016

  1. Activation of PPARβ/δ prevents hyperglycaemia-induced impairment of Kv7 channels and cAMP-mediated relaxation in rat coronary arteries

    Clinical Science, Vol. 130, Núm. 20, pp. 1823-1836

  2. Effects of quercetin in a rat model of hemorrhagic traumatic shock and reperfusion

    Molecules, Vol. 21, Núm. 12